Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Galapagos Loses Potential Ticket To America As Crohns Trial Flops

Executive Summary

The company reported the Phase III DIVERSITY trial of Jyseleca did not meet its primary endpoint in Crohn’s disease, closing another path to the US market.

You may also be interested in...



Galapagos Says Goodbye To Jyseleca And Streamlines Operations

The Belgium-based biotech is transferring the rights to its only marketed product to Italy’s Alfasigma in a move aimed at cutting costs and tightening its focus on its early-stage immunology and oncology pipeline.

Galapagos Could Give Up On Jyseleca Over JAK Class Woes

New chief financial officer Thad Huston said that Galapagos was evaluating “various strategic options for Jyseleca,” the company’s only revenue source, given that the landscape for the JAK class in Europe “has changed significantly over the past six months.”

Galapagos Sees Global Market For Point-Of-Care CAR-T But Is Still On M&A Trail

Paul Stoffels is continuing his transformation of Galapagos into a company with CAR-T and small molecule platforms and is aiming to seal more M&A deals before the end of this year.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147888

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel